The Eltrombopag antitumor effect on hepatocellular carcinoma

Currently, sorafenib is the only available chemotherapeutic agent for advanced hepatocellular carcinoma (HCC), but it cannot be used in patients with liver cirrhosis (LC) or thrombocytopenia. In these cases, sorafenib is likely effective if given in combination with treatments that increase the numb...

Descripción completa

Detalles Bibliográficos
Autores principales: KUROKAWA, TOMOHIRO, MURATA, SOICHIRO, ZHENG, YUN-WEN, IWASAKI, KENICHI, KOHNO, KEISUKE, FUKUNAGA, KIYOSHI, OHKOHCHI, NOBUHIRO
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2015
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599203/
https://www.ncbi.nlm.nih.gov/pubmed/26397763
http://dx.doi.org/10.3892/ijo.2015.3180

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4599203/
https://www.ncbi.nlm.nih.gov/pubmed/26397763
http://dx.doi.org/10.3892/ijo.2015.3180

Ejemplares similares